Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- BCTXW
- Price
- 0.02
- Stock movement up
- +0.00 (13.87%)
- Company name
- BriaCell Therapeutics Corp
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Market cap
- -
- Ent value
- 1.01M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 367.28%
- 1 year return (CAGR)
- -94.01%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
BCTXW does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | - |
| EPS (TTM) | -15.16 |
| FCF per share (TTM) | -15.31 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -80.28K |
| Operating income (TTM) | -30.22M |
| Net income (TTM) | -28.56M |
| EPS (TTM) | -15.16 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.71M |
| Net receivables | 1.17M |
| Total current assets | 11.35M |
| Goodwill | 0.00 |
| Intangible assets | 180.71K |
| Property, plant and equipment | 0.00 |
| Total assets | 13.08M |
| Accounts payable | 2.13M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 3.32M |
| Total liabilities | 3.72M |
| Shareholder's equity | 9.35M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -28.84M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -28.84M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -305.43% |
| Return on Assets | -218.42% |
| Return on Invested Capital | -305.43% |
| Cash Return on Invested Capital | -308.47% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.01 |
| Daily high | 0.02 |
| Daily low | 0.01 |
| Daily Volume | 5K |
| All-time high | 6.55 |
| 1y analyst estimate | - |
| Beta | 1.92 |
| EPS (TTM) | -15.16 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| BCTXW | S&P500 | |
| Current price drop from All-time high | -99.70% | -0.89% |
| Highest price drop | -99.74% | -19.00% |
| Date of highest drop | 21 Jan 2026 | 8 Apr 2025 |
| Avg drop from high | -98.10% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 300 days | 89 days |
COMPANY DETAILS
Marketcap
-
Marketcap category
Small-cap
Description
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner